Profile of tivozanib and its potential for the treatment of advanced renal cell carcinoma.
Profile of tivozanib and its potential for the treatment of advanced renal cell carcinoma.
复制标题
DOI：
10.2147/dddt.s31442
复制
发表时间：
2013
期刊：
影响因子：
--
通讯作者：
Cowey CL
中科院分区：
文献类型：
--
作者：
Cowey CL
Tivozanib是一种新型血管内皮生长因子受体酪氨酸激酶抑制剂（VEGF TKI）。在其他VEGF TKIs中，tivozanib因其选择性激酶抑制特性以及抑制VEGF受体1和2的高效能而脱颖而出。Tivozanib已经在多个临床试验中进行了评估，包括I期和II期试验，证明了对晚期透明细胞肾细胞癌（RCC）患者的安全性和有效性。一项关键的随机III期试验比较了tivozanib和sorafenib在转移性透明细胞RCC患者中的一线使用。我们将对替沃扎尼的临床发展和这些重要研究的结果进行综述。此外，将讨论tivozanib在目前美国食品和药物管理局批准的晚期RCC药物中的潜在位置。
Tivozanib is a novel vascular endothelial growth factor receptor tyrosine kinase inhibitor (VEGF TKI). Among other VEGF TKIs, tivozanib stands apart due to its selective kinase inhibitory properties as well as its high potency for inhibiting VEGF receptors 1 and 2. Tivozanib has been evaluated in several clinical trials including a Phase I and Phase II trial demonstrating safety and efficacy for patients with advanced clear cell renal cell carcinoma (RCC). A pivotal randomized Phase III trial comparing the front-line use of tivozanib to sorafenib in patients with metastatic clear cell RCC has been reported. The clinical development of tivozanib and results of these important studies will be reviewed. Also, the potential placement of tivozanib among currently US Food and Drug Administration approved agents for advanced RCC will be discussed.